Riskpilot← Back to searchSign inGet full accessBluefish Pharmaceuticals AB (publ)
ABActiveOrg 5566739164Gävlegatan 22Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200522 employees
Revenue 2025
SEK 542,8M
+19% vs 2024
EBITDA margin
-3.1%
+75% vs 2024
Equity ratio
5.2%
Financial strength
Net profit 2025
SEK -24M
+53% vs 2024
| Revenue | SEK 542,8M | +19% |
| EBITDA | SEK -16,7M | +75% |
| Net profit | SEK -24M | +53% |
| Total assets | SEK 562,9M | +14% |
| Equity | SEK 29,2M | +26% |
| Employees | 22 | — |
Legal name
Bluefish Pharmaceuticals AB (publ)
Org number
5566739164
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3 januari 2005
Share capital
SEK 21 585 000
Employees
22 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna externa firmatecknaren Paulsson, Jan Christian Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva handel med läkemedel, naturläkemedel, naturmedel, hälso- och sjukvårdsprodukter ävensom därmed förenlig verksamhet.
Address
Gävlegatan 22
Phone
+4686795070
Email
hampus.olsson@bluefishpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 399 066 | 370 979 | 545 069 | 455 863 | 542 788 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 29 609 | −18 079 | −1 552 | −68 257 | −16 730 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 29 609 | −18 079 | −1 552 | −68 257 | −16 730 |
| Net financials | −11 990 | −25 132 | −76 208 | −1 791 | −48 528 |
| Profit before tax | 23 876 | −27 887 | −40 672 | −50 779 | −23 969 |
| Tax | −0 | −0 | −0 | −42 | −23 |
| Net profit | 23 876 | −27 887 | −40 672 | −50 821 | −23 992 |
| Item | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 445 939 | 420 818 | 581 007 | 492 435 | 562 940 |
| Equity | 64 076 | 36 189 | 11 018 | 23 191 | 29 200 |
| Long-term debt | 39 487 | 22 108 | 3 897 | 850 | 3 754 |
| Short-term debt | 342 376 | 362 521 | 566 092 | 468 395 | 529 987 |
| Total debt | 381 863 | 384 629 | 569 989 | 469 245 | 533 741 |
EBITDA margin
-3.1%
This company
15.8%
Market median
-120% vs market
20202025
Equity ratio
5.2%
This company
38.2%
Market median
-86% vs market
20202025
Return on equity
-82.2%
This company
18.4%
Market median
-547% vs market
20202025
Net profit margin
-4.4%
This company
8.1%
Market median
-154% vs market
20202025
Asset turnover
0.96×
This company
1.12×
Market median
+14% vs market
20202025
Debt / equity
18.28×
This company
0.62×
Market median
-2848% vs market
20202025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-01-01 – 2023-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JC Chief Executive Officer | Chief Executive Officer | 2025 |
PI | Audit | 2026 |
HO External Signatory | External Signatory | 2025 |
| Former (11) | ||
JH Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
PR Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
BM Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
LA Chief Executive Officer | Chief Executive Officer | 2021 – 2023 |
TM Chief Auditor | Chief Auditor | 2023 – 2025 |
EO Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
HF External Signatory | External Signatory | 2023 – 2025 |
CB Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
AB Chief Executive Officer | Chief Executive Officer | 2025 – 2025 |
CC Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
AK Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2025 | |
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Former (5) | ||
| Chairman | 2021 – 2021 | |
| Chairman | 2020 – 2021 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 92% | 92% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Färna Invest AB
Bluefish Pharmaceuticals AB (publ) (this company)Bfph Portugal Unipessoal LdaBluefish Pharma Sp z o oBluefish Pharma LtdBluefish Pharmaceuticals Pvt LtdMenta3 Pharmaclub S.L.Bluefish Pharma France SarlMenta3 Pharmaclub SlBluefish Pharma Holding LtdBLUEFISH PHARMA HOLDING LTDBluefish Pharma Sp. z O.O.Bluefish Pharma GmbhBluefish Pharma GmbhBluefish Pharma SluBluefish Pharma Sp. Z O.O.BLUEFISH PHARMA FRANCE SARLBLUEFISH PHARMA GMBHBLUEFISH PHARMA LTDBLUEFISH PHARMA SLUBFPH PORTUGAL UNIPESSOAL LDABLUEFISH PHARMACEUTICALS PVT LTDBLUEFISH PHARMA GMBHBLUEFISH PHARMA SP. Z O.O.MENTA3 PHARMACLUB S.L.Board members of Bluefish Pharmaceuticals AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jane Harriet Benyamin | Chief Executive Officer | 0 companies |
| Per Ragnar Johannes Hedström | Chief Executive Officer | 0 companies |
| Jan Christian Paulsson | Chief Executive Officer | 0 companies |
| Per Inge Andreas Pettersson | Audit | 0 companies |
| Berit Margareta Lindholm | Chief Executive Officer | 0 companies |
| Lillie Anna-Greta Johanna Sjöberg | Chief Executive Officer | 0 companies |
| Therése Mathilda Utengen | Chief Auditor | 0 companies |
| Hampus Olof Olsson | External Signatory | 0 companies |
| Erik Olof Ekman | Chief Executive Officer | 0 companies |
| Hans Fredrik Sehlstedt | External Signatory | 0 companies |
| Can Bektas | Chief Executive Officer | 0 companies |
| Annika Beata Bladh Muskantor | Chief Executive Officer | 0 companies |
| Charlotte Catrine Holmstrand | Chief Executive Officer | 0 companies |
| Anna Kristina Svanberg | Chief Executive Officer | 0 companies |
| Björn Andreas Engström | Board of Directors | 0 companies |
| Alf Gerald Engström | Chairman | 0 companies |
| Erika Elisabeth Kjellberg Eriksson | Chairman | 0 companies |
| Per Fredrik Lehmann | Board of Directors | 0 companies |
| Gunilla Birgitta Ruth Spongh | Chairman | 0 companies |
| Synne Hermansen Røine | Deputy Board Member | 0 companies |
| Wenche Nelly A Rolfsen Sandsborg | Board of Directors | 0 companies |
| Michael Bodd | Board of Directors | 0 companies |
| Eva Ulrika Saers | Board of Directors | 0 companies |